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Secondary hyperparathyroidism (HPT) is characterized by persistent 
hypersecretion of parathyroid hormone (PTH), and produces characteristics 
of hyperparathyroid bone disease and a variety of biochemical and hormonal 
derangements. Management of uremic secondary HPT involves both 
prevention and treatment. Among preventive measures are attempts to 
control serum phosphate and serum calcium concentrations through dietary 
restriction, administration of phosphate binders, and calcium supplementation. 
Treatment with a vitamin D analog such as calcitriol returns plasma calcium 
concentrations toward normal and suppresses PTH secretion. The availability 
of a parenteral formulation of calcitriol, and new information regarding 
alternative routes of administration and regimens employing oral pulse dosing 
have renewed interest in calcitriol for the management of uremic secondary 
HPT. 
(Pharmacotherapy 1996; 16(4):6 19-630) 
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Summary 
Hyperparathyroidism (HPT) is defined as the 
excess or inappropriate secretion of parathyroid 
hormone (PTH) associated with hyperplasia of 
the parathyroid glands. Secondary HPT 
associated with chronic renal failure results from 
long-standing chronic hypocalcemic stimulation 
and partial end organ resistance to the metabolic 
actions of PTH.l This condition occurs almost 
universally in patients with chronic renal failure 
in whom persistent hypersecretion of PTH can 
produce characteristics of hyperparathyroid bone 
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disease, including osteitis fibrosa and 
osteosclerosis, and a variety of biochemical and 
hormone derangements that may in turn cause 
the dysfunction of other organ systems.24 
The medical management of this disorder is 
multimodal and creates a constant challenge to 
the health care team. Practitioners are continually 
searching for new and innovative approaches to 
slow the progression of bone disease and  
improve patients’ quality of life. A recent 
advance in this area is the use of newer dosing 
strategies for parenteral calcitriol. 
Pathophysiology of Secondary HPT 
The pathogenesis of secondary HPT is 
complex. Hypocalcemia, the recognized 
stimulus for the synthesis and secretion of PTH, 
is the product of several factors, including 
phosphate retention, decreased production of 
active vitamin D (1,25-(OH)zD3) secondary to 
decreased renal mass and hyperphosphatemia, 
reduced gastrointestinal absorption of calcium 
due to both decreased production of active 
vitamin D and depressed calcium transport in the 
uremic state, and peripheral resistance to the 
actions of PTH.’”, 
To understand the disturbances in mineral 
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homeostasis, primarily calcium and phosphate, 
in patients with chronic renal failure, i t  is 
necessary to appreciate the interrelationships 
between PTH and 1,25-(OH)zD3, the control 
mechanisms involved in their synthesis and 
secretion, and their modes of action (Figure 1). 
In humans, the chief regulators of calcium 
homeostasis are PTH and 1,25-(OH)zD3. 
Parathyroid hormone is the principal hormone 
involved in the routine regulation of ionized 
calcium levels in the extracellular fluid, with 
1 ,25-(OH)2D3 playing a key role in maintaining 
calcium balance. The two also exercise 
regulatory effects on each other. For example, 
PTH stimulates the production of 1 ,25-(OH)2D3 
by activating the renal a-hydroxylase enzyme. 
Active vitamin D suppresses the synthesis and 
release of PTH by inhibit ing PTH gene 
transcription through interaction with specific 
receptor proteins in target cells that have high 
affinity and specificity for 1,25-(OH)2D3.6, ' 
Active vitamin D enters the circulation and is 
transported by the vitamin D-binding protein to 
target tissues where it interacts with native 
receptors. The net result is that it augments the 
intestinal absorption of calcium and phosphorus 
from the diet. High levels of serum calcium in 
turn suppress PTH secretion by a feedback 
mechanism.6, 
The kidneys lose a substantial portion of their 
ability to produce 1,25-(OH)2D3 in patients with 
uremia and reduced functional renal mass 
(Figure 2). This results in a decline in the 
intestinal absorption of calcium and eventual 
hypocalcemia. Hypocalcemia is further 
perpetuated by hyperphosphatemia, a direct 
consequence of decreased phosphate clearance.' 
Decreased clearance i n d  subsequent 
accumulation of biologically active as well as 
inactive PTH fragments in the circulation also 
occur in renal impairment. Reduced clearance of 
other hormones such as catecholamines may 
contribute to excessive PTH secretion in  
secondary HPT through their ability to promote 
PTH production by an unknown mechani~m.~? 
In addition, the mechanisms that normally 
suppress PTH release are impaired. In 
individuals with normal renal function, a high 
serum calcium concentration acts as a trigger to 
suppress PTH synthesis and s,ecretion. In uremic 
patients with hyperplastic parathyroid glands, the 
concentration of calcium necessary to suppress 
PTH secretion is higher (so-called shift in set 
point) since the parathyroids are relatively 
insensitive to negative feedback  control^.^ 
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Figure 1.  Parathyroid hormone axis regulation. 
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shift in calcium set point are the leading causes 
of impaired suppression of PTH secretion. 
Therefore, adequate suppression of PTH 
secretion may require high and potentially toxic 
serum calcium levels. lo Peripheral resistance to 
the effects of PTH and the persistent stimulus of 
hypocalcemia leads to redirection of PTH activity 
to bone, causing the integrity of bone to be 
sacrificed in an effort to maintain normal levels 
of calcium. 
The role of phosphate retention in the 
pathogenesis of secondary HPT was the subject 
of recent study Phosphate accumulation in renal 
failure is known to contribute to HPT indirectly 
by causing hypocalcemia through 1,25-( OH)lD3 
suppression and the reciprocal relationship with 
serum calcium concentrations. Reversal of 
hyperphosphatemia by dietary restriction, 
phosphate binders, and dialysis can therefore 
help correct hypocalcemia. Further evidence 
from a study in  rats suggests that  dietary 
phosphate restriction may suppress PTH 
secretion through a mechanism independent of 
1,25-(0H)lD3 or serum calcium concentrations." 
This reinforces the importance of dietary phos- 
phate restriction and phosphate management in 
the treatment of this condition. 
Conditions outside of the PTH axis can also 
contribute to the development or exacerbation of 
HPT in renal failure. Accumulation of aluminum 
can impair bone mineralization and contribute to 
the heterogeneity of the osteodystrophy that 
occurs in renal failure. l2 Traditionally, the most 
common source of aluminum intake in patients 
receiving dialysis was aluminum-containing 
phosphate binders, however, these are no longer 
recommended as first-line treatment of hyper- 
phosphatemia. Thus, aluminum bone disease is 
much more rare now than in the past.5 Metabolic 
acidosis has also been correlated with secondary 
HPT, and it has been suggested that correcting 
pH could help reduce PTH 1e~els . l~ 
Clinical Manifestations 
Clinical manifestations of secondary HPT in 
renal disease vary depending on disease severity. 
Patients with renal failure typically have 
hypocalcemia and hyperphosphatemia. Bone 
pain, muscle weakness, pruritus, and skeletal 
abnormalities (renal osteodystrophy) are 
common.12 The skeletal abnormalities include 
osteomalacia, generalized osteopenia, osteo- 
J 
Toxicity - Mcrabolic acidosis 
Figure 2. Pathophysiology and treatment of secondary hyperparathyroidism associated with renal failure. 
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sclerosis, and osteitis fibrosa cystica (increased 
osteoclastic resorption of the calcified bone with 
replacement by fibrous tissue). Skeletal 
pathology may reflect osteitis due to the 
excessive production of PTH in the initial stages 
of renal impairment. In later stages, effects of the 
impaired formation of 1 ,25-(OH)2D3 become 
more evident and osteomalacia predominates. 
Generalized osteopenia and subsequent patho- 
logic fractures could also occur, particularly in 
patients undergoing long-term hem~dialysis.~, l2 
The most significant extraskeletal ramification 
of persistently elevated PTH levels is metastatic 
calcification. This is the end product of calcium- 
phosphate precipitation into arteries, joints, soft 
tissues and the viscera. It usually occurs when 
the calcium-phosphate product exceeds 72-80 
mg/dl.l23 l3 
Diagnosis 
Distinctly elevated levels of immunoreactive 
PTH (iPTH), electrolyte abnormalities such as 
decreased calcium and increased phosphate 
serum concentrations, and bone pain are early 
signs of parathyroid dysfunction. In addition, 
bone fractures, increased bone density observed 
on radiographs, bone biopsy, or bone scan; and 
elevations in serum alkaline phosphatase levels 
are all highly suggestive of secondary HPT.”. 14, l5 
Parathyroid hormone exists in plasma as an 
intact 84-amino acid single-chain polypeptide 
hormone, and also as amino (N) terminal and 
carboxy (C) terminal hormone fragments. The 
biologic activity of PTH resides in its N terminal 
one-third portion. In peripheral plasma, the 
predominant form of iPTH is generally inactive 
and consists largely of C terminal fragments5 
To detect PTH levels i n  serum, various 
radioimmunoassays specific for the different 
segments of the hormone have been developed. 
The double-antibody or intact  PTH radio- 
immunoassay measures the concentration of the 
whole polypeptide.16 The N terminal, C 
terminal, and midregion immunoassays detect 
the concentrations of hormone fragments in 
serum.3- Debate continues as to which of these 
assays provides the most reliable assessment of 
parathyroid f ~ n c t i o n . ~ .  I6-l8 Consequently, the 
clinician should become familiar with the one 
performed locally, recognize i ts  potential 
limitations, and interpret the results accordingly. 
Management 
Management of secondary HPT of chronic 
renal failure requires both prevention and 
treatment. The initial preventive focus is 
directed at maintaining serum calcium and 
phosphate levels within the normal range. In the 
face of fulminant disease, treatment requires 
reducing parathyroid mass and healing the bone 
disease and other complications.’ If these 
measures fail to achieve a desirable outcome, 
parathyroidectomy is the definitive treatment. 
However, the availability of Ealcitriol is important 
in reducing the need for parathyroidectomy in 
these  patient^.'^ 
It is essential to control serum phosphate levels 
to slow the progression of secondary HPT and, in 
turn, renal osteodystrophy and extraskeletal 
calcification. Restriction of dietary phosphate 
intake, administration of phosphate binders, and 
dialysis are generally employed to decrease 
phosphate retention in renal f a i l ~ r e . ~ ’ - ~ ~  As 
mentioned, aluminum-containing phosphate 
binders are generally not prescribed as first-line 
agents, and calcium carbpnate and calcium 
acetate are the phosphate-binding agents of 
choice. The chief limitation of these products is 
hypercalcemia, which can be offset by reducing 
the calcium content of dialysate solutions. Some 
authors recommend that standard dialysate 
concentrations of calcium should be lowered to 
accommodate the safe oral intake of calcium 
necessary for phosphate binding.20 
Persistently low levels of serum calcium occur 
routinely in patients with chronic renal failure. 
Although calcium-containing phosphate binders 
rectify this problem somewhat, supplementation 
of dietary intake with elemental calcium 1.0-1.5 
g/day may be necessary to maintain concen- 
trations at or near the upper limit of normal, thus 
reducing the stimulus for PTH secretion. To 
reduce the risk of metastatic calcification, neither 
of these methods should be begun until the 
product of the calcium-phosphate serum 
concentrations is stabilized below 70 mg/d1.24 
Aluminum-containing phosphate binders may be 
given for a short time in conjunction with strict 
dietary phosphorus restriction and dialysis until 
the risk is reduced. 
Calcitriol 
The discovery that calcitriol ( 1,25-(OH)2D3) is 
produced by renal tissue, and the observation 
that uremic patients have low serum levels of 
1,25-(OH)zD3, led to the conclusion that 
alterations in renal calcitriol synthesis, and 
therefore abnormalities in the vitamin D-PTH 
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axis, contribute to the pathogenesis of secondary 
HPT in patients with progressive renal failure." 
In the past, calcitriol was administered to replace 
the loss of endocrine function and to treat 
persistent hypo~alcemia .~  The interaction of 
calcitriol with its intestinal receptors to promote 
the intestinal absorption of calcium, increase 
serum calcium levels, and reduce PTH synthesis 
and secretion is viewed as its indirect a ~ t i o n . ~ ~ - ~ ~  
Recently, interest has focused on the ability of 
calcitriol to suppress PTH production directly 
through interaction with receptors on the 
parathyroid glands. It is generally believed that 
many of the manifestations of secondary HPT can 
be reversed by treatment with vitamin D analogs, 
which are sterols with hypercalcemic and 
antirachitic activity. Reduced functional renal 
mass and the kidneys' inability to metabolize 
precursor products to active vitamin D effectively 
make calcitriol and l-a-hydroxyvitamin D3 the 
agents of choice in uremic patients. These agents 
require no metabolism by renal a-hydroxylase to 
become a ~ t i v e . ~ * - ~ ~  
Two desired effects of calcitriol are returning 
plasma calcium concentrations to normal and 
suppressing PTH to levels slightly above (1.5-2.5 
times) the upper limits of Lower levels 
may cause adynamic bone disease and predispose 
patients to deposition of aluminum on mineralized 
bone surfaces.l03 2 9 v  30 Low bone turnover rates 
also cause impaired bone formation by reducing 
the degree of microcallus formation; that is, the 
ability of the normal skeleton to repair bone 
damage and modify bone structure to various 
biochemical demands.13 
Calcitriol was initially marketed is an oral 
dosage form (Rocaltrol; Roche Laboratories, 
Nutley NJ). It received approval from the Food 
and Drug Administration for the management of 
hypocalcemia in patients receiving long-term 
renal dialysis. An initial dosage of 0.25 pg/day 
can be t i trated unt i l  the desired effect is 
attained.31 Interest in  calcitriol for HPT 
secondary to renal failure was renewed because 
of the availability of a parenteral formulation and 
new information concerning alternative routes of 
administration and regimens. Parenteral 
calcitriol (Calcijex; Abbott Laboratories, Chicago, 
IL) has the same approved indication as the oral 
product, with a recommended initial dosage of 
0.5 pg 3 timedweek titrated to an optimum 
clinical effect.32 The average wholesale price of 
oral calcitriol in 1995 was $1.04 for 0.25 pg and 
$1.66 for 0.5 pg. Parenteral calcitriol has an 
average wholesale price of $12.24 for 1.0 pg.33 
Oral Administration 
A number of studies reported the clinical 
usefulness and limitations of oral calcitriol in the 
treatment of secondary HPT.34, 35 The minor PTH 
suppressive effect and symptom resolution with 
traditional daily doses of 0.25-1 pg are the result 
of increases in serum calcium concentration 
rather than a direct effect on PTH. Oral calcitriol 
also has a significant first-pass effect, with the 
primary site of metabolism being the 
Consequently, peripheral concentrations are 
reduced after oral administration when compared 
with intravenous administration. 
The high frequency of hypercalcemic and 
hyperphosphatemic events associated with oral 
calcitriol secondary to its local action on the gut 
may also limit the application of this 
f ~ r m u l a t i o n . ~ ~  However, some investigators 
attempted to take advantage of the hypercalcemic 
side effect and used the agent's indirect action to 
suppress PTH levels. High dosages (average 
0.17-1.7 pg/day) were given to raise plasma 
calcium concentrations in 16 pediatric patients 
undergoing continuous ambulatory peritoneal 
dialysis (CAPD) .38 All patients were maintained 
on aluminum-containing phosphate binders in a 
dosage adjusted to maintain the serum phosphate 
below 6.0 mg/dl. The calcitriol dosages were 
actually within the recommended range for 
children, yet serum calcium concentrations 
increased significantly from a baseline of 9.9 * 
0.9 to 11.0 * 0.6 mg/dl (2.4-2.8 mmoVL, p<O.OOl). 
Serum albumin concentrations averaged 3.3 f 0.5 
and 3.6 * 0.5 g/dl at the beginning and end of the 
study, respectively (NS). Other changes were 
decreases in alkaline phosphatase from 530 * 397 
to 204 * 551 IU/L (p<O.Ol) and in mid-region 
iPTH of 113 131 pEq/ml (p<0.005). Baseline 
radiographic findings remained unchanged 
throughout the the study, indicating limited 
progression of renal disease and possible clinical 
benefit. 
It was theorized that the general failure of oral 
daily calcitriol to return biochemical abnormalities 
of secondary HPT to normal was due to inadequate 
concentrations of calcitriol alone or in conjunction 
with insufficient dietary calcium ~upplementation.~~ 
Eight hemodialysis-dependent patients were given 
increasing dosages of calcitriolO.5-1 pg/day until 
the serum concentrations exceeded 15 pg/ml 
(normal 10-50 pg/ml). Calcium carbonate was 
administered concomitantly with meals in an 
amount sufficient to titrate the serum calcium 
between 10 and 10.5 mg/dl (2.5-2.6 mmoVL). 
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Aluminum-containing phosphate binders were 
adjusted to maintain the serum phosphorus 
concentration between 3.0 and 6.0 mg/dl, and 
the dialysate calcium concentration was main- 
tained at 3.5 mEq/L. Transient hypercalcemia 
caused temporary discontinuation of calcitriol in 
several patients. Reductions in intact PTH from 
968 k 176 to 365 k 149 pg/ml (p<0.05) and 
serum alkaline phosphatase levels from 295 +- 65 
to 97 k 20 U/L (p<0.05) were seen after 15 
months of therapy. No correlation to changes in 
clinical status was made. 
To reduce the frequency of hypercalcemic 
events related to the agent while still achieving 
the high plasma concentrations required to cause 
direct suppression of PTH, 19 uremic patients 
received oral pulse calcitriol 4.0 pg twice/week 
for 6 months.40 All patients were maintained on 
oral aluminum hydroxide to keep serum 
phosphorus concentrations between 4.0 and 6.0 
mg/dl. Dialysate calcium concentrations were 
held constant at 3.5 mEq/L. Decreases in  C 
terminal iPTH from 18.4 k 2.6 to 9.6 f 2.2 ng/ml 
(p<O.OOl) and alkaline phosphatase from 759 +- 
203 to 270 f 65 I U L  (p<O.OOl) occurred after 6 
months of calcitriol therapy. Three patients 
experienced episodes of hypercalcemia 
(11.0-12.5 mg/dl, 2.74-3.1 mmol/L, albumin 
concentrations not reported) during the fourth 
month  of the study. Symptoms (mostly 
gastrointestinal) and serum calcium levels were 
reduced after temporary discontinuation of 
calcitriol. Thus, high oral doses of calcitriol 
administered intermittently can cause partial 
reversal of PTH hypersecretion. 
The reduction of iPTH (double-antibody 
method) was even greater, from 108 k 13.8 to 
44.1 * 8.3 pmoVL (p<O.Ol), after administration 
of calcitriol4 pg twicdweek for 12 weeks to nine 
patients receiving long-term hemodia1y~i .s .~~ 
Details concerning calcium ingestion, use of 
phosphate binders,  and  dialysate calcium 
concentration were not reported. Differences in 
techniques of measuring PTH serum levels in 
these studies may account for the variations in 
PTH suppression. 
Five patients receiving CAPD were administered 
oral calcitriol 5 pg twice/week for 6 months.42 
Calcium carbonate was continued as a phosphate 
binder throughout the study, and the dialysate 
calcium concentration was held at 3.5 mEqL. 
Serum albumin levels did not change signifi- 
cantly during the study. Based on an overall 60% 
decrease in iPTH levels using various assays, the 
authors concluded that oral pulse therapy has a 
direct action on PTH levels and may be an option 
for the management of secondary HPT in patients 
who cannot tolerate large daily doses of calcitriol 
or who receive no substantial benefit from 
traditional daily regimens. 
The timing of oral calcitriol administration 
may also influence the frequency and severity of 
hypercalcemia, possibly because less absorbable 
calcium is available for ralcitr iol-induced 
intestinal absorption at  night than in  the 
morning. The occurrence of hypercalcemia was 
lower in 35 hemodialysis patients who took daily 
doses of calcitriol at bedtime compared with the 
morning (50% and 80%, respectively; P < O . O ~ ) . ~ ~  
Furthermore, the severity of the hypercalcemic 
events in patients receiving bedtime doses was 
less than that in patients given daily morning 
doses. These patients also received either 
calcium carbonate or calcium acetate as phos- 
phate binders in equivalent phosphate-binding 
doses. Doses of calcium carbonate were about 
twice those of calcium acetdte, yet no difference 
in the frequency of hypercalcemia was observed 
between the groups. These results agree with 
those of other studies comparing calcium 
carbonate and calcium acetate.30 
In summary, success in achieving suppression 
of PTH depends on achieving relatively high 
serum calcitriol concentrations. Intestinal 
degradation of orally administered calcitriol and 
inadequate levels of the agent at peripheral sites 
are the major reasons why traditional daily doses 
fail to suppress PTH secretion adequately and 
halt progression of disease. Therapy is also 
limited by hypercalcemia and hyperphosphatemia 
due to the drug’s local effects on the gastro- 
intestinal tract. Development of hypercalcemia 
does not appear to be influenced by the calcium 
salt used for phosphate binding. However, a 
reduction of the dialysate calcium concentration 
may allow use of calcium-containing phosphate 
binders in association with pulse calcitriol. 
Intravenous Administration 
Intravenous calcitriol is a synthetic formulation 
that is available as a sterile aqueous solution for 
injection.32 It was first given to patients who 
failed oral therapy. Potential advantages of the 
intravenous over the oral route are a reduced 
potential for hypercalcemia, higher peripheral 
calcitriol levels, and a greater potential for 
reducing PTH serum levels. The reduced 
hypercalcemic effect is thought to be due to a 
diminished local effect on the intestinal 
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absorption of calcium. Intravenous administration 
also negates intestinal metabolism and the loss of 
a substantial fraction of the drug before it reaches 
the general circulation. Blood levels are therefore 
higher than with oral dosing, resulting in higher 
calcitriol concentrations delivered to the 
parathyroid glands.*'- 37 
Twenty hemodialysis-dependent subjects 
received short-term, intermittent, intravenous 
calcitriol 0.5-4 pg 3 times/week after dialysis for 
8 weeks.36 The result was marked suppression of 
midregion and C terminal PTH levels of 70.1 k 
3.2% from baseline (~10.001) .  Serum calcium 
increased from a baseline mean of 7 to 9.4 k 0.3 
mg/dl (1.74-2.34 mmoVL), with related serum 
phosphate elevations. These findings suggest 
that intravenous calcitriol has a significant 
suppressive effect on PTH release and potential 
clinical utility in patients with secondary HPT. 
Mild hypercalcemic episodes may occur. 
The effectiveness of long-term, intermittent, 
intravenous calcitriol infusions on bone disease 
associated with secondary HPT was evaluated in 
12 hemodialysis patients with refractory disease 
who were under consideration for surgical 
para thyro ide~tomy.~~ Dosages of 1-2.5 pg 3 
times/week were administered over an average of 
11.5 months. Aluminum-containing phosphate 
binders were given to maintain serum phosphorus 
concentrations below 6.0 mg/dl. Neither oral 
calcitriol nor calcium was administered during 
the study; dialysate calcium concentrations 
ranged from 3-3.5 mM/L. Levels of iPTH, 
measured by either an N terminal or C terminal 
assay, decreased by a mean of 48% over the 
duration of the study, and serum calcium 
increased from 2.55 f 0.03 to 2.67 +- 0.05 mmoVL 
(10.2-10.7 mg/dl, p<O.Ol). Serum phosphate 
concentrations remained relatively unchanged. 
The mean rate of bone formation was reduced 
59% ( ~ ~ 0 . 0 1 ) .  Thirty hypercalcemic episodes (> 
2.87 mmol/L, > 11.5 mg/dl) occurred in 10 
patients, with 1 patient discontinuing therapy 
early due to persistent hypercalcemia. However, 
no patient reported symptoms related to 
hypercalcemia. The authors concluded that 
intravenous calcitriol lowers the rate of bone 
turnover by lowering serum PTH levels, thus 
decreasing the stimulus for bone resorption and 
bone stem cell (osteoblast) proliferation. This 
suppressive effect was documented in other 
studies.". 4547 
In an attempt to avoid the hypercalcemia 
related to high doses, 21 hemodialysis-dependent 
patients with mild to moderate secondary HPT 
received low-dose intravenous calcitriol (mean 
maximum dose 0.92 0.11 pg) after dialysis for 
1-2 years.48 Patients were given calcium 
carbonate with each meal in an amount adjusted 
to maintain serum phosphorus concentrations 
less than 6.0 mg/dl. Aluminum-containing 
phosphate binders were given only when the 
serum phosphorus exceeded 7.0 mg/dl. Dialysate 
calcium concentrations were maintained at 3.0 or 
3.5 mEq/L. Calcitriol decreased N terminal iPTH 
to 48 f 6% and 29 2 5% of baseline values at 12 
and 24 months,  respectively (p<O.OOOl). 
Increases in serum calcium concentration over 
baseline were noted at  12  months (2.22 k 
0.04-2.41 f 0.03 mmoVL, 8.9 f 0.2-9.7 k 0.1 
mg/dl, p<0.03). No further elevations in calcium 
concentrations occurred with continued calcitriol 
therapy. With the exception of one patient, 
hypercalcemia did not affect calcitriol dosage 
adjustments. Serum phosphate concentrations 
remained unaltered. These findings suggest that 
low-dose intravenous calcitriol is effective in 
reducing PTH levels in patients with mild to 
moderate secondary HPT without causing 
significant hypercalcemia or hyperphosphatemia. 
In contrast, significant hyperphosphatemic 
events occurred in 60% of 83 hemodialysis- 
dependent patients in a 4-month multicenter 
An initial dose of intravenous calcitriol 
0.015 pg/kg was administered in conjunction 
with phosphate binders (aluminum salts, calcium 
carbonate, or a combination) to maintain serum 
phosphorus concentrations below 6.0 mg/dl. 
Reductions in intact PTH levels with this regimen 
were not statistically significant but were seen in 
72% of patients. Baseline ionized calcium and 
alkaline phosphatase levels remained relatively 
unchanged throughout the study. 
Low-dose intravenous calcitriol appears to 
result in few hypercalcemic events, bu t  
discrepancies concerning the degree of PTH 
suppression that occurs make its efficacy in the 
management of secondary HPT of renal failure 
questionable. Another major concern is the 
number of significant hyperphosphatemic 
episodes with this regimen in the face of adjuvant 
phosphate binders. Whether this strategy 
reduces the risk of prolonged suppression of 
bone turnover and subsequently lessens 
predisposition for adynamic or aluminum-related 
bone disease requires further study. 
Despite all the clinical investigations, 
controversy remains regarding the optimum 
calcitriol dosage, the most effective route of 
administration, the effect of therapy on the 
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regression of parathyroid gland hyperplasia, and 
its long-term efficacy in patients with uremic 
hyperparathyroidism. To resolve these issues, the 
first randomized, double-blind, placebo- 
controlled comparison of oral pulse and intra- 
venous calcitriol was conducted in 19 patients 
receiving hemodialysis over 36  weeks.49 
Although the protocol prescribed adjusting 
calcitriol from a starting dosage of 2 pg to a 
maximum of 4.0 pg 3 timedweek, the maximum 
dosages administered averaged only 2.5 and 2.4 
pg 3 timedweek in the intravenous and oral 
arms, respectively. The development of 
hypercalcemia and refractory hyperphosphatemia 
precluded further increases. All patients received 
similar daily calcium supplementation and low 
dialysate calcium 1.25 mMol/L. Control of 
phosphate levels required progressive increases in 
phosphate-binding capacity of 61% and 117% 
over controls in the intravenous and oral groups, 
respectively, administered in the form of calcium 
carbonate or aluminum hydroxide, although 70% 
of patients in the former and 100% in the latter 
group experienced at least one hyperphosphatemic 
episode. Hypercalcemic episodes occurred in 
80% and 56% of subjects, respectively. The 
frequency of hyperphosphatemic and hyper- 
calcemic events was not  considered to be 
significantly different between groups. 
The investigators also noted that a t  the 
maximum tolerated dosage of calcitriol, serum 
1,25-dihydroxyvitarnin D levels were significantly 
greater 60 minutes after intravenous (389 
pmol/L) than after oral administration (128 
pmol/L) ,49 yet no significant difference in the 
overall degree of PTH suppression was observed 
(maximum average reduction 43%, p=0.016). 
Neither route caused significant reduction in 
average parathyroid gland volume or number 
despite the substantial decline in PTH levels. 
The authors concluded that the two routes of 
administration were equivalent in the treatment 
of uremic secondary HPT. Hyperphosphatemia 
and hypercalcemia severely limited the upward 
titration of calcitriol dosages, and may therefore 
have limited the potential for therapeutic effects. 
The results also challenge the finding of fewer 
hypercalcemic events associated with intravenous 
calcitriol reported by others.27. 36, 37, 48 
Intravenous calcitriol is a safe and effective 
means to suppress parathyroid gland secretion, 
reduce serum PTH, and lessen the rate of bone 
turnover in uremic patients with secondary HPT. 
Undesirable effects such as hypercalcemia and 
hyperphosphatemia can occur, however. Whether 
the magnitude of these effects is markedly 
reduced compared with oral calcitriol therapy is 
still a topic of debate. 
Other Routes of Administration 
With the increasing use of CAPD and 
continuous cycling peritoneal dialysis (CCPD) 
for the management of uremic patients, effective 
and convenient alternatives to intravenous 
calcitriol are necessary. Intraperitoneal, subcu- 
taneous, and intramuscular routes of calcitriol 
administration have been investigated in this 
patient population. These alternative routes are 
believed to be other methods by which the 
intestinal degradation of calcitriol is bypassed, 
allowing for heightened delivery of the agent to 
peripheral target 50 
Continuous ambulatory peritoneal dialysis 
causes only small fluctuations in PTH levels, 
even with its removal of PTH and the main- 
tenance of calcium in the upper limits of normal 
with oral calcitriol. I t  wak hypothesized that 
PTH suppression could be accomplished better 
by increasing calcium absorption from the 
dialysate (calcium mass transfer) with higher 
dialysate concentrations of calcium.5* 51  In 
addition, intraperitoneal administration of 
calcitriol could augment the PTH suppressive 
effect by delivering high serum levels of calcitriol 
to the periphery. 
To test the plausibility of the hypothesis and to 
determine the effects of intraperitoneal calcitriol 
on PTH levels, 11 patients received CAPD with a 
standard dialysate containing 3.5 mEq/L calcium 
for a 2-month control period. After this they 
received dialysis with a dialysate fortified to 
calcium 4.0 mEq/L for another 2 months.  
Calcium absorption was increased with the 
fortified dialysate compared with the standard 
one (84 * 6.2 vs 37.8 f 16.9 mg/day), however, 
no changes in  ionized calcium levels were 
observed. Modest suppression of PTH levels to 
84% of control values (p<0.05) was also reported 
with the calcium-fortified dialysate. 
Intraperitoneal calcitriol 0.5-2 pg/day was 
subsequently administered in  2 L dialysate 
containing either 4.0 or 3.5 mEq/L calciurdday 
to the 11 patients for 3 months.50 With the 
institution of intraperitoneal therapy, increases in 
ionized calcium levels from 5.31 f 0.09 to 10.5 f 
0.17 mg/dl (1.32-2.62 mmoVL) and corresponding 
decreases in serum PTH levels to 53.9 * 7.9% of 
control values (p<O.Ol) occurred. Thus, the 
primary effect of intraperitoneal calcitriol on 
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PTH levels could be attributed to elevations in 
serum calcium concentrations. 
Loss of calcitriol due to interaction with the 
peritoneal dialysis delivery system is a major 
disadvantage associated with the intraperitoneal 
route. Two in vitro studies infused radiolabeled 
calcitriol admixed with dialysate into standard 
dialysate bags and tubing and then immediately 
drained the dialysate. Although this procedure 
was done to minimize contact time, only 62-63% 
of the dose was delivered through the system.50* 52
Longer periods of contact resulted in even greater 
loss of calcitriol, with 26% remaining at 20 
hours.52 
A pharmacokinetic comparison of intra- 
peritoneal, oral, and intravenous routes of 
administration confirmed these findings, Six 
adolescent peritoneal dialysis-dependent patients 
received a one-time dose of calcitriol 60 ng/kg." 
The bioavailability of intraperitoneal calcitriol 
was 66% of that after intravenous administration 
and essentially equivalent to that after oral 
administration. Although direct instillation of 
injectable calcitriol into the peritoneal cavity 
would be expected to minimize this interaction, 
no improvement in bioavailability was found.50 
A 2-fold increase in the intraperitoneal dose of 
calcitriol (1 20 ng/kg) resulted in bioavailability 
comparable with that of an intravenous dose of 
60 ng/kg. The similarity in the percentage of 
delivered drug in the in vitro and in vivo studies 
leads one to conclude that intraperitoneal 
bioavailability is explained by the adherence of 
calcitriol to the plastic materials of the dialysis 
system, although it was suggested that the agent 
could also be lost through metabolic and 
degradatory processes after intraperitoneal 
admini~tration.~' 
Due to the bioavailability problems associated 
with intraperitoneal administration, subcutaneous 
administration was proposed as an alternative 
parenteral route for patients receiving peritoneal 
dialysis. A one-time dose of 2 pg resulted in 
peak serum concentrations 1 hour  after 
admini~tration,~~ and mean serum concentrations 
persisted above baseline levels for 24 hours. 
Seven uremic patients receiving CAPD who 
had severe secondary HPT were given 
subcutaneous calcitriol 2 pg 3 timedweek for 8 
weeks.54 On average, a 55% reduction in intact 
PTH levels was noted from baseline (349 _+ 
26-158 * 20 pg/ml, p<0.04). In the five patients 
with reduced PTH levels there was an inverse 
relationship between plasma PTH and calcium 
levels at  week 6. The suppression of PTH was 
believed to occur secondary to elevated levels of 
calcium, although a direct effect could not be 
ruled out. 
Uremic pediatric patients had persistently 
elevated PTH levels and recurrent episodes of 
hypercalcemia after a period of oral calcitriol 
administration and calcium s~pplementa t ion .~~ 
Intramuscular calcitriol 10.5-16.9 ng/kg 
(0.375-1.2 pg) 3 timedweek for up to 6 weeks 
reduced alkaline phosphatase activity 5 1-59% 
and PTH levels 47-51%. 
The intraperitoneal,  subcutaneous,  and 
intramuscular routes of calcitriol administration 
are promising for the management of secondary 
HPT in renal failure. However, they must be 
compared directly with the oral and intravenous 
routes. 
The Role of Calcitriol in the Management of Renal 
0 s  teody s t rophy 
The place of calcitriol and the timing of its 
administration (prevention vs therapy) in the 
progression of renal osteodystrophy remains 
unclear. Some investigators advocate early 
administration in patients with moderate renal 
impairment, even in those with no symptoms, 
normal serum alkaline phosphatase concen- 
trations, and normal bone radiographs. They 
argue that if calcitriol therapy is delayed, PTH 
hypersecretion may never be reversed since the 
hyperplastic parathyroid glands will continue to 
secrete supraphysiologic concentrations of 
A prospective, double-blind, controlled trial of 
oral calcitriol was conducted in 16 patients with 
creatinine clearances of 20-59 m l / r n i n ~ t e . ~ ~  
Although biochemical and radiologic markers of 
renal osteodystrophy were within normal limits, 
all patients had abnormal bone histology Most 
received calcitriol 0.25 pg/day; those receiving 
0.5 pg/day were likely to require a dosage 
reduction due to hypercalcemia. Treatment for 
12 months resulted in a significant reduction in 
alkaline phosphatase within the normal range 
and an insignificant reduction in C terminal PTH 
levels. There were significant reductions in 
indexes of bone formation and resorption and in 
the number of osteoblasts. 
The finding of reduced bone formation is of 
concern, since the goal of therapy is to bring 
rapid bone turnover back to normal, not to cause 
adynamic bone disease. It was suggested that 
smaller dosages of 0.25 pg/day or an intermittent 
schedule with 1 month on and 1 month off could 
PTH, 10,47,55 
628 PHARMACOTHERAPY Volume 16, Number 4,1996 
alleviate the suppression of bone formation that 
sometimes results with this 
Another area of concern in patients in early 
stages of renal disease is the potential for 
calcitriol's deleterious effects on renal f~nct ion.~ '  
An early trial reported a more rapid decline in 
renal function after several months of therapy 
compared with changes seen before therapy.58 
More recent reports failed to document any 
deleterious effects on renal function, despite 
episodes of prolonged hypercalcemia, which have 
the potential to cause more rapid progression of 
renal failure.59. 6o These findings are encouraging, 
and with careful monitoring and a modest dosage 
in the range of 0.25 pg/day, calcitriol may prevent 
progression of renal bone disease in patients with 
mild to moderate renal impairment. 
The agent has beneficial effects in patients with 
end-stage renal failure with no overt evidence of 
bone disease.61 The success of oral or intravenous 
high-dose pulse therapy is apparent, although 
some believe that the risk of adynamic bone 
disease associated with calcitriol can be avoided 
by giving calcium carbonate alone in  high 
dosages (6 g/day) or in conjunction with reduced 
calcium dialysate as first-line treatment. One 
group advocates such an approach, reserving 
vitamin D3 derivatives for patients with more 
severe disease when iPTH levels exceed twice the 
upper limit of normal.30 Clearly, comparative 
trials must assess the efficacy of the various 
prophylactic regimens. 
New Vitamin D Analogs 
Since the hypercalcemic effect of oral calcitriol 
may preclude its use in the management of 
secondary HPT, the search continues for new 
vitamin D analogs that have suppressive effects 
on the parathyroid glands without increasing 
intestinal calcium absorption.12 One analog of 
calcitriol currently under clinical investigation is 
19-nor-l,25-(OH)2D2. This agent exhibited 
potent suppressive effects on PTH secretion in 
rats, with low calcemic and phosphatemic 
activity compared with calcitriol.62 This 
noncalcemic analog may be effective in the 
treatment of secondary HPT, providing another 
option for patients who cannot tolerate calcitriol. 
Other noncalcemic vitamin D analogs that 
have been isolated include the 24-homo D3 
analogs MC903, 22-oxacalcitriol, and 1,25- 
(OH)2-16-ene-23-yne-D3.63x 64 To date, the 
therapeutic effects of these compounds have been 
assessed only in animal trials. 
Summary 
Many questions regarding calcitriol and its 
efficacy in the management of secondary HPT 
remain unanswered. These lingering questions 
are due in part to lack of understanding of the 
pathogenesis of that disorder in patients with 
renal failure. Based on the available literature, 
intravenous administration appears to be the 
most promising because of i t s  ability to deliver 
high calcitriol levels to the periphery and 
subsequently suppress PTH. Although all of the 
routes of administration are associated with some 
degree of hypercalcemia, the intravenous route 
may cause the fewest hypercalcemic effects. 
When intravenous therapy is not feasible, oral 
pulse therapy is an  option. I t  can be 
administered at  night or other times of low 
calcium ingestion to reduce the potential for 
hypercalcemia. There is little documentation of 
the intraperitoneal,  subcutaneous,  and 
intramuscular routes. 
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